GlassScriptPhysician profile
Bryan A Lewis
NPI 1508198094
$1,858.16
in general payments reported to CMS, 2019-2025
19 companies · $697 in 2025
The $697 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $237 · 2023: $419 · 2024: $505 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,620.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.96 | 2023-2025 | |
| Glaxosmithkline, LLC. | $320.50 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $215.27 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $158.80 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceuticals, INC. | $119.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.56 | 2023-2025 | Jardiance, Tradjenta |
| Phathom Pharmaceuticals, INC. | $109.67 | 2025 | Voquezna |
| Pfizer INC. | $96.47 | 2024-2025 | |
| Lilly USA, LLC | $62.99 | 2023-2025 | Mounjaro, Zepbound |
| Abbott Laboratories | $52.28 | 2024-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $45.88 | 2024-2025 | Capvaxive, Gardasil 9, Rotateq |
| Takeda Pharmaceuticals U.S.A., INC. | $40.02 | 2025 | Vpriv |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.11 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $18.43 | 2025 | Auvelity |
| Pulmonx Corporation | $17.65 | 2025 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $16.60 | 2024 | |
| Vivus LLC | $14.83 | 2025 | Qsymia |
| Exact Sciences Corporation | $14.10 | 2024 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $13.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.